Breast cancer in young patients. Peculiarities of prognosis and adjuvant hormone therapy (a literature review)

Author:

Kravchenko D. N.1,Parokonnaya A. A.1,Nechushkin M. I.1,Nikitina E. A.1,Hakurinova N. D.1

Affiliation:

1. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Abstract

Breast cancer (BC) keeps being the most predominant malignant disease in women. In recent years, a trend towards “rejuvenescence” of the disease has been observed that affects its features. Despite modern methods of diagnosis and complex treatment used in young patients, survival in this age group are inferior that’s associated with biological and morphological peculiarities of BC in young age. Gradually are being collected data according to what age might be an independent factor exacerbating prognosis. For BC patients younger 40 years, various aspectsof hormone therapy remain ambiguous: prolonged tamoxifen use, aromatase inhibitors prescription, ovarian function suppression, a role of chemotherapy-induced amenorrhea on prognosis. The issue of appropriate, personalized adjuvant hormone therapy of BC is complex and heterogenous that requires a necessity to further conduct international randomized trials.

Publisher

Publishing House ABV Press

Subject

Pharmacology (medical),Obstetrics and Gynecology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference62 articles.

1. Ferlay J., Shin H.R., Bray F. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893–917. PMID: 21351269. DOI: 10.1002/ijc.25516.

2. Aksel' E.M. Statistika zlokachestvennykh novoobrazovanii zhenskikh polovykh organov. Opukholi zhenskoi reproduktivnoi sistemy 2009;(1–2):76–80. DOI: 10.17650/1994-4098-2009-0-1-2-76-80. [Aksel’ E.M. Statistics of gynecological malignancies. Opukholi zhenskoy reproduktivnoy sistemy = Tumors of Female Reproductive System 2009; (1–2):76–80. (In Russ.)].

3. Portnoi S.M., Shendrikova T.A. Ad\"yuvantnaya gormonoterapiya raka molochnoi zhelezy dlitel'nost'yu 10 let: za i protiv. Opukholi zhenskoi reproduktivnoi sistemy 2013;(3–4): 50–3. [Portnoy S.M., Shendrikova T.A. Ten-year adjuvant hormone therapy for breast cancer: pros and cons. Opukholi zhenskoy reproduktivnoy sistemy = Tumors of Female Reproductive System 2013;(3–4):50–3. (In Russ.)].

4. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2015 g. Pod red. A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoi. Dostupno po: http://oncology-association.ru/docs/medstat/sostoyznie/2015.pdf. [Situation with cancer care in Russia in 2015. Ed. by A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Available at: http://oncology-association.ru/docs/medstat/sostoyznie/2015.pdf. (In Russ.)].

5. Zlokachestvennye novoobrazovaniya v Rossii v 2010 g. Pod red. V.I. Chissova, V.V. Starinskogo, G.V. Petrovoi. M., 2012. 260 s. [Malignant tumors in Russia in 2010. Ed. by V.I. Chissov, V.V. Starinskiy, G.V. Petrova. Moscow, 2012. 260 p. (In Russ.)].

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3